

RECEIVED

MAY 09 2001

0410 1624,

PATENT

Docket No. 128019203802

#3 PS
S/18

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231 on March 9, 2001.

Name

Crystal Fong

Crystal Fong

In re Application for:

GARY D. GLICK

Examiner: Not Assigned

Serial No.: 09/767,283

Group Art Unit: Not Assigned

Filing Date: January 22, 2001

For: PRO-APOPTOTIC
BENZODIAZEPINES

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97**

Commissioner for Patents
Washington, D.C. 20231


Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Some of the copies of the documents were previously submitted in an Information Disclosure Statement dated December 29, 2000 and a Supplemental Information Disclosure Statement dated January 9, 2001, directed to the related parent application U.S. Serial Number 09/700,101, and accordingly, copies are not included herewith. Enclosed is a copy of the PTO 1449 Statement filed in connection with U.S. Serial No. 09/700,101. This protocol conforms with 37 C.F.R. § 1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record.

RECEIVED

MAY 09 2001

TECH CENTER 1600/2900



This Information Disclosure Statement is submitted:

- within three months of the application filing date or before receipt of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- After receipt of a first Office Action on the merits but before a final Office Action or Notice of Allowance.
 - A fee is required. A check in the amount of \$* is enclosed.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below; according, no fee is believed to be due.
 - After receipt of a final Office Action or Notice of Allowance, but before payment of the issue fee.

Accordingly, a Petition requesting consideration of the Information Disclosure Statement, an authorization to charge our deposit account, and a Certification under 37 C.F.R. § 1.97(e) are provided herein.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.


This Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the U.S. Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 50-0974** referencing **128019203802**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: March 9, 2001

By:


Antoinette F. Konski
Registration No. 34,202

Baker & McKenzie
660 Hansen Way
Palo Alto, California 94304
Telephone: (650) 856-2400
Facsimile: (650) 856-9299

EXAMINER: _____ **DATE CONSIDERED:** _____
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

154157.1

199459v1

Form PTO-1449 INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)				Attorney's Docket No. 128019-203801 Applicant(s)	Application Serial No. 09/700,101 Gary D. GLICK, et al.		
				Filing Date: November 8, 2000	Group Art Unit: Unassigned		
U.S. PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
	1.	02/28/1978	4,076,823	Wade, et al.			
	2.	08/29/1978	4,110,327	Szarvasi			
	3.	01/22/1985	4,495,104	Klaubert, et al.			
	4.	06/14/1988	4,751,223	Glamkowski, et al.			
	5.	08/20/1991	5,041,438	Hsu			
	6.	06/28/1994	5,324,726	Bock, et al.			
	7.	01/28/1997	5,597,915	Chambers, et al.			
	8.	07/07/1998	5,776,946	McGeer, et al.			
	9.	01/19/1999	5,861,380	Gyorkos, et al.			
	10.	12/21/1999	6,004,942	Firestein, et al.			
	11.	06/27/2000	6,080,588	Glick			
FOREIGN PATENT DOCUMENTS							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES NO
	12.	06/04/2000	WO 00/19200	PCT			
OTHER DOCUMENTS (Including author, title, date, pertinent pages, etc.)							
Examiner Initials	Ref. No.	Title					
	13.	Adachi, M., et al., "Aberrant Transcription Caused by the Insertion of an Early Transposable Element in an Intron of the Fas Antigen Gene of <i>lpr</i> Mice," <i>Proc. Natl. Acad. Sci. USA</i> - 90:1756-1760 (1993)					
	14.	Adelman, N.E., et al., "Treatment of (NZB X NZW)F ₁ Disease with Anti-I-A Monoclonal Antibodies," <i>J. Exp. Med.</i> - 158:1350-1355 (1983)					
	15.	Baader, S.L., et al., "Uptake and Cytotoxicity of Ascorbic Acid and Dehydroascorbic Acid in Neuroblastoma (SK-N-SH) and Neuroectodermal (SK-N-LO) Cells," <i>Anticancer Research</i> - 14:221-228 (1994)					
	16.	Beale, P.J., et al., "BCL-2 Family Protein Expression and Platinum Drug Resistance in Ovarian Carcinoma," <i>British Journal of Cancer</i> - 82(2):436-440 (2000)					
	17.	Boojamra, C.G., et al., "Solid-Phase Synthesis of 1,4-Benzodiazepine-2,5-Diones. Library Preparation and Demonstration of Synthesis Generality," <i>J. Org. Chem.</i> - 62:1240-1256 (1997)					
	18.	Bunin, B.A., et al., "A General and Expedient Method for the Solid-Phase Synthesis of 1,4-Benzodiazepine Derivatives," <i>J. Am. Chem. Soc.</i> - 114:10997-10998 (1992)					
	19.	Bunin, B.A., et al., "The Combinatorial Synthesis and Chemical and Biological Evaluation of a 1,4-Benzodiazepine Library," <i>Proc. Natl. Acad. Sci. USA</i> - 91:7408-4712 (1994)					
	20.	Chumakov, A.M., et al., "Analysis of p53 Transactivation Through High-Affinity Binding Sites," <i>Oncogene</i> - 8:3005-3011 (1993)					
	21.	Cohen, P.L., et al., "Lpr and gld: Single Gene Models of Systemic Autoimmunity and Lymphoproliferative Disease," <i>Annu. Rev. Immunol.</i> - 9:243-269 (1991)					
	22.	Crabtree, R.H., "A New Type of Hydrogen Bond," <i>Science</i> - 282:2000-2001 (1998)					
	23.	Desoize, B., "Anticancer Drug Resistance and Inhibition of Apoptosis," <i>Anticancer Research</i> - 14:2291-2294 (1994)					
EXAMINER:				DATE CONSIDERED:			
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in compliance. Include a copy of this form with next communication to applicant.							
154157.1							
193696v1							

Form PTO-1449 INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)		Attorney's Docket No. 128019-203801 Applicant(s)	Application Serial No. 09/700,101 Gary D. GLICK, et al.
		Filing Date: November 8, 2000	Group Art Unit: Unassigned
OTHER DOCUMENTS (Continuation) <i>(including author, title, date, pertinent pages, etc.)</i>			
24.	Doble, A., et al., "Labelling of Peripheral-Type Benzodiazepine Binding Sites in Human Brain with [³ H]PK 11195: Anatomical and Subcellular Distribution," <i>Brain Research Bulletin</i> - 18:49-61 (1987)		
25.	Donadio, J.V., et al., "Immunosuppressive Drug Therapy in Lupus Nephritis," <i>American Journal of Kidney Diseases</i> - 21(3):239-250 (1993)		
26.	Ermak, T.H., et al., "Treatment of Murine Lupus with Monoclonal Antibody to L3T4," <i>Laboratory Investigation</i> - 61(4):447-456 (1989)		
27.	Gallant, J.E., et al., "Incidence and Natural History of Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Disease Treated with Zidovudine," <i>The Journal of Infectious Diseases</i> - 166:1223-1227 (1992)		
28.	Garcia-Calvò, M., et al. "Inhibition of Human Caspases by Peptide-Based and Macromolecular Inhibitors," <i>The Journal of Biological Chemistry</i> - 273(49):32608-32613 (1998)		
29.	Gorczyca, W., et al., "Induction of DNA Strand Breaks Associated with Apoptosis During Treatment of Leukemias," <i>Leukemia</i> - 7(5):659-670 (1993)		
30.	Gordon, C., et al. "Chronic Therapy with Recombinant Tumor Necrosis Factor- α in Autoimmune NZB/NZW F ₁ Mice," <i>Clinical Immunology and Immunopathology</i> - 52:421-434 (1989)		
31.	Gordon, E.M., et al., "Applications of Combinatorial Technologies to Drug Discovery. 2. Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions," <i>Journal of Medicinal Chemistry</i> - 37(10):1385-1401 (1994)		
32.	Hahn, B.H., et al., "Influence of Cyclophosphamide and Other Immunosuppressive Drugs on Immune Disorders and Neoplasia in NZB/NZW Mice," <i>Arthritis and Rheumatism</i> - 18(2):145-152 (1975)		
33.	Hang, L., et al., "A Spontaneous Rheumatoid Arthritis-Like Disease in MRL/1 Mice," <i>J. Exp. Med.</i> - 155:1690-1701 (1982)		
34.	Horowitz, R.E., et al., "Cyclophosphamide Treatment of Mouse Systemic Lupus Erythematosus," <i>Laboratory Investigation</i> - 21(3):199-206 (1969)		
35.	Itoh, N., et al., "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis," <i>Cell</i> - 66:233-243 (1991)		
36.	Koopman, W.J., et al., "The MRL-Ipr/Ipr Mouse. A Model for the Study of Rheumatoid Arthritis," <i>Scand. J. Rheumatology - Suppl</i> 75:284-289 (1988)		
37.	Korsmeyer, S.J., "Bcl-2 Initiates a New Category of Oncogenes: Regulators of Cell Death," <i>Blood</i> - 80(4):879-886 (1992)		
38.	Liu, J.R., et al., "Bcl-xL is Expressed in Ovarian Carcinoma and Modulates Chemotherapy-Induced Apoptosis," <i>Gynecologic Oncology</i> - 70:398-403 (1998)		
39.	Los, M., et al., "The Role of Caspases in Development, Immunity, and Apoptotic Signal Transduction: Lessons from Knockout Mice," <i>Immunity</i> - 10:629-639 (1999)		
40.	Luria, et al., "General Virology - 3 rd edition, pp. 436-446 (1978) - Eds. John Wiley & Sons, New York		
41.	Marino, M., et al., "Prevention of Systemic Lupus Erythematosus in MRL/Ipr Mice by Administration of an Immunoglobulin-Binding peptide," <i>Nature Biotechnology</i> - 18:735-739 (2000)		
42.	McDonnell, T.J., et al., "Progression from Lymphoid Hyperplasia to High-Grade Malignant Lymphoma in Mice Transgenic for the t(14;18)," <i>Nature</i> - 349:254-256 (1991)		
43.	Nagata, S., "Human Autoimmune Lymphoproliferative Syndrome, a Defect in the Apoptosis-Inducing Fas Receptor: A Lesson from the Mouse Model," <i>J. Hum. Genet.</i> - 43:2-8 (1998)		
44.	Okuyama, H., et al., "Analysis of Defective Delayed-Type Hypersensitivity in Autoimmune Mice Bearing Ipr Gene," <i>Clin. Exp. Immunol.</i> - 63:87-94 (1986)		
45.	Okuyama, H., et al., "Effect of Cyclophosphamide Pretreatment on Defective Delayed-Type Hypersensitivity in Autoimmune-Prone MRL Mice," <i>Int. Arch. Allergy Appl. Immunol.</i> - 88:394-401 (1989)		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation informs with MPEP 609. Draw a line through the citation if not in consideration. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)		Attorney's Docket No. 128019-203801 Applicant(s) Gary D. GLICK, et al.	Application Serial No. 09/700,101 Group Art Unit: Unassigned
		Filing Date: November 8, 2000	

OTHER DOCUMENTS (Continuation)

(including author, title, date, pertinent pages, etc.)

46. Ozols, R.F., "Paclitaxel Plus Carboplatin in the Treatment of Ovarian Cancer," *Seminars in Oncology* - 26(1)(Supp. 2):84-89 (1999)
47. Pestell, K.E., et al., "Characterisation of the P53 Status, BCL-2 Expression and Radiation and Platinum Drug Sensitivity of a Panel of Human Ovarian Cancer Cell Lines," *Int. J. Cancer* - 77:913-918 (1998)
48. Raynaud, F.I., et al., "Intracellular Metabolism of the Orally Active Platinum Drug JM216: Influence of Glutathione Levels," *Br. J. Cancer* - 74(3):380-386 (1996)
49. Russell, J.H., et al., "Mature T Cells of Autoimmune *lpr/lpr* Mice have a Defect in Antigen-Stimulated Suicide," *Proc. Natl. Acad. Sci. USA* - 90:4409-4413 (1993)
50. Sakata, K., et al., "Role of Fas/FasL Interaction in Physiology and Pathology: The Good and the Bad," *Clinical Immunology and Immunopathology* - 87(1):1-7 (1998)
51. Sandstrom, P.A., et al., "Autocrine Production of Extracellular Catalase Prevents Apoptosis of the Human CEM T-Cell Line in Serum-Free Medium," *Proc. Natl. Acad. Sci. USA* - 90:4708-4712 (1993)
52. Schoemaker, H., et al., "Specific High-Affinity Binding Sites for [³H]Ro5-4864 in Rat Brain and Kidney," *The Journal of Pharmacology and Experimental Therapeutics* - 225(1):61-69 (1983)
53. Schwab, M., et al., "Amplified DNA with Limited Homology to *myc* Cellular Oncogene is Shared by Human Neuroblastoma Cell Lines and a Neuroblastoma Tumour," *Nature* - 305:245-248 (1983)
54. Scott, C.F., et al., "Comparison of Antigen-Specific T Cell Responses in Autoimmune MRL/mp-lpr/lpr and MRL/Mp-+/+ Mice," *The Journal of Immunology* - 132(2):633-639 (1984)
55. Sentman, C.L., et al., "bcl-2 Inhibits Multiple Forms of Apoptosis but not Negative Selection in Thymocytes," *Cell* - 67:879-888 (1991)
56. Sheppard, R.C., et al., "Acid-Labile Resin Linkage Agents for Use in Solid Phase Peptide Synthesis," *Int. J. Peptide Protein Res.* - 20:451-454 (1982)
57. Stevens, S.Y., et al., "Non Nucleic Acid Inhibitors of Protein-DNA Interactions Identified Through Combinatorial Chemistry," *J. Am. Chem. Soc.* - 118:10650-10651 (1996)
58. Sugimoto, T., et al., "Determination of Cell Surface Membrane Antigens Common to Both Human Neuroblastoma and Leukemia-Lymphoma Cell Lines by a Panel of 38 Monoclonal Antibodies," *JNCI* - 73(1):51-57 (1984)
59. Swanson, P.C., et al., "High Resolution Epitope Mapping of an Anti-DNA Autoantibody Using Model DNA Ligands," *J. Immunology* - 152(5):2601-2612 (1994)
60. Swanson, P.C., et al., "Ligand Recognition by Murine Anti-DNA Autoantibodies," *J. Clin. Invest.* - 97(7):1748-1760 (1996)
61. Takahashi, T., et al., "Generalized Lymphoproliferative Disease in Mice, Caused by a Point Mutation in the Fas Ligand," *Cell* - 76:969-976 (1994)
62. Theofilopoulos, A.N., et al., "Murine Models of Systemic Lupus Erythematosus," *Advances in Immunology* - 37:269-390 (1985)
63. Thompson, C.B., "Apoptosis in the Pathogenesis and Treatment of Disease," *Science* - 267:1456-1462 (1995)
64. Watanabe-Fukunaga, R., et al., "Lymphoproliferation Disorder in Mice Explained by Defects in Fas Antigen that Mediates Apoptosis," *Nature* - 356:314-317 (1992)
65. White, E., "Life, Death, and the Pursuit of Apoptosis," *Genes & Development* - 10:1-15 (1996)
66. Wu, G.Y., et al., "Receptor-Mediated *In Vitro* Gene Transformation by a Soluble DNA Carrier System," *The Journal of Biological Chemistry* - 262(10):4429-4432 (1987)
67. Wyllie, A.H., "The Genetic Regulation of Apoptosis," *Current Opinion in Genetics & Development* - 5:97-104 (1995)
68. Zamzami, N., et al., "Mitochondrial Control of Nuclear Apoptosis," *J. Exp. Med.* - 183:1533-1544 (1996)
69. Zoratti, M., et al., "The Mitochondrial Permeability Transition," *Biochimica et Biophysica Acta* - 1241:139-176 (1995)

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conflict. Considered. Include a copy of this form with next communication to applicant.

